Danaher reports Q2 2026: Revenue $6.27B, Net earnings $870M, Adj. diluted EPS $1.94

Danaher reported second-quarter 2026 results with revenue of $6.27 billion and net earnings of $870 million, or $1.23 per diluted share. Adjusted diluted net earnings per common share (non-GAAP) were $1.94, up 8.0% year-over-year, while non-GAAP core revenue rose 3.0%. The company generated $1.53 billion in operating cash flow and $1.27 billion of non-GAAP free cash flow in the quarter.

Financial Highlights

• Sales (Revenue): $6,265 million for the three-month period ended June 26, 2026.
• Gross profit: $3,611 million for the three-month period ended June 26, 2026.
• Operating profit: $1,127 million for the three-month period ended June 26, 2026.
• Net earnings: $870 million (GAAP) for the three-month period ended June 26, 2026; basic and diluted net earnings per common share: $1.23.
• Adjusted diluted net earnings per common share (non-GAAP): $1.94 for the quarter; full-year 2026 guidance increased to $8.45–$8.60 (non-GAAP).
• Cash flow: Operating cash flow $1,534 million and free cash flow (non-GAAP) $1,265 million for the quarter.

Business Highlights

• Core sales growth: Non-GAAP core revenue increased 3.0% year-over-year in Q2 2026; core revenue excluding respiratory testing increased 4.5%.
• Segment performance: Life Sciences delivered its strongest quarter in several years; Biotechnology and Diagnostics showed differing trends with Diagnostics benefiting from respiratory testing contributions.
• Order trends: Bioprocessing orders grew mid-teens in the quarter despite customer project timing impacting bioprocessing revenue.
• Strategic activity: Completion of the Masimo acquisition earlier than anticipated supported raised full-year adjusted EPS guidance; pending Leica Biosystems acquisition of StatLab expected to close by end of 2026 subject to approvals.
• Liquidity and capital deployment: Strong operating cash conversion and free cash flow support capital deployment optionality noted by management.

Original SEC Filing: DANAHER CORP /DE/ [ DHR ] - 8-K - Jul. 20, 2026